NCT06462053View on ClinicalTrials.gov

Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

March 1, 2027

Conditions
Early Low Rectal Cancer
Interventions
RADIATION

Short-course radiotherapy

Short-course radiotherapy: 25Gy/5Fx

DRUG

PD-1 antibody (Toripalimab)

Toripalimab 240mg d1 q3w

RADIATION

Long-course radiotherapy

Long-course radiation: 50Gy/25Fx

DRUG

Oxaliplatin

Oxaliplatin: 130mg/m2 d1 q3w

DRUG

Capecitabine

Xeloda

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER